```html

Zollinger‑Ellison Syndrome and Unexplained Weight Loss

What is Zollinger‑Ellison syndrome weight loss?

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) form in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyper‑acidic environment overwhelms the protective mucus barrier, causing severe peptic ulcer disease, chronic diarrhea, and malabsorption.

Weight loss in ZES is not caused by the tumor itself, but by the cascade of gastrointestinal symptoms that prevent the body from absorbing nutrients efficiently. Persistent diarrhea, abdominal pain, and vomiting lead to a net calorie deficit, while the high‑acid environment can inactivate digestive enzymes and damage the lining of the small intestine.

According to the Mayo Clinic, up to 70 % of patients with ZES experience unexplained weight loss at the time of diagnosis.

Common Causes

Weight loss associated with ZES may be precipitated or worsened by several other conditions that either increase gastric acidity or impair nutrient absorption. The most frequently encountered include:

• Gastrinomas (Zollinger‑Ellison syndrome) – the primary cause.
• Peptic ulcer disease – chronic ulceration can cause pain‑induced anorexia.
• Chronic diarrhea – loss of fluids and electrolytes reduces caloric intake.
• Pancreatic exocrine insufficiency – insufficient enzyme secretion leads to malabsorption.
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) – inflammation interferes with absorption.
• Small‑intestinal bacterial overgrowth (SIBO) – competes for nutrients and produces gas.
• Hyperthyroidism – accelerates metabolism and may coexist with endocrine tumors.
• Malignancies of the stomach or pancreas – can cause similar ulcerative and malabsorptive patterns.
• Celiac disease – gluten‑induced villous atrophy worsens malabsorption.
• Severe gastroesophageal reflux disease (GERD) with esophagitis – chronic pain may diminish food intake.

Associated Symptoms

Weight loss in ZES rarely occurs in isolation. The syndrome produces a constellation of gastrointestinal (GI) and systemic signs:

• Recurrent or refractory peptic ulcers – often multiple and located beyond the duodenum.
• Abdominal pain – typically epigastric, worsening after meals.
• Chronic watery diarrhea – may be nocturnal and persist despite dietary changes.
• Vomiting – can be projectile if ulcer perforation occurs.
• Steatorrhea (fatty stools) – indicates fat malabsorption.
• Heartburn and acid reflux – due to excess gastric acid.
• Fatigue and weakness – result of electrolyte loss and nutrient deficiency.
• Iron‑deficiency anemia – chronic blood loss from ulcerations.
• Low serum albumin – a marker of protein‑calorie malnutrition.
• Bone demineralization (osteopenia/osteoporosis) – long‑standing acid excess can affect calcium absorption.

When to See a Doctor

Weight loss is a red flag when it is unintentional and accompanied by any of the following:

• Persistent epigastric pain that does not improve with over‑the‑counter antacids.
• Diarrhea lasting more than 2 weeks, especially if it is oily or foul‑smelling.
• Repeated episodes of vomiting or hematemesis (vomiting blood).
• Difficulty swallowing or a sensation of food getting stuck.
• Sudden, rapid weight loss (>5 % of body weight in 6 months) without diet changes.
• Signs of anemia (pallor, shortness of breath, dizziness).
• New‑onset heartburn that is unresponsive to proton‑pump inhibitors (PPIs).

If you notice any of these, schedule an appointment with a primary‑care physician or gastroenterologist promptly. Early evaluation can prevent complications such as ulcer perforation, severe malnutrition, or metastatic spread of a gastrinoma.

Diagnosis

Diagnosing ZES involves confirming excess gastrin production and locating the gastrinoma. A typical work‑up includes:

1. Laboratory Tests

• Fasting serum gastrin level – Values > 1000 pg/mL are highly suggestive, especially when accompanied by low gastric pH (< 2).
• Gastric pH measurement – Acidic pH confirms hyper‑secretion.
• 24‑hour urinary acid output – Elevated in severe cases.
• Basic metabolic panel – Detects electrolyte disturbances (e.g., low potassium, magnesium).
• Complete blood count (CBC) – Checks for anemia.
• Serum albumin and pre‑albumin – Markers of nutritional status.

2. Imaging Studies

• Endoscopic ultrasound (EUS) – Provides high‑resolution images of the pancreas and duodenum.
• Contrast‑enhanced CT scan or MRI – Identifies primary tumors and metastatic lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – Detects neuroendocrine tumors with high sensitivity.

3. Endoscopic Evaluation

• Upper endoscopy (EGD) – Visualizes ulcers, obtains biopsies, and can assess for Helicobacter pylori infection, which may coexist.

4. Secretin Stimulation Test

If fasting gastrin is borderline, intravenous secretin (a hormone that paradoxically raises gastrin in gastrinomas) is administered and gastrin levels are re‑measured. A rise > 120 pg/mL strongly supports ZES.

Treatment Options

Management aims to (1) control gastric acid hyper‑secretion, (2) eradicate or control the gastrinoma, and (3) correct nutritional deficits.

Medical Management

• Proton‑pump inhibitors (PPIs) – High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; they reduce acid output by > 90 % and often reverse ulcer disease.
• Histamine‑2 receptor antagonists (H2 blockers) – May be added for breakthrough symptoms but are less effective than PPIs.
• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin secretion and may shrink small gastrinomas.
• Antidiarrheal agents – Loperamide or diphenoxylate‑atropine can control diarrhea while underlying acid excess is addressed.
• Pancreatic enzyme replacement therapy (PERT) – Treats concurrent exocrine insufficiency causing steatorrhea.
• Vitamin and mineral supplementation – Iron, vitamin B12, calcium, and fat‑soluble vitamins (A, D, E, K) are often required.

Surgical & Interventional Options

• Enucleation or segmental resection – Preferred for isolated, non‑metastatic gastrinomas and can be curative.
• Pancreaticoduodenectomy (Whipple procedure) – Considered for larger tumors involving the head of the pancreas.
• Liver-directed therapies – Radiofrequency ablation or embolization for hepatic metastases.
• Targeted systemic therapy – Everolimus or sunitinib for progressive metastatic disease.
• Peptide receptor radionuclide therapy (PRRT) – Uses radiolabeled somatostatin analogues for tumors expressing somatostatin receptors.

Home & Lifestyle Measures

• Eat small, frequent meals to reduce gastric load.
• Avoid foods that trigger acid production: caffeine, alcohol, spicy or fatty foods.
• Stay hydrated; replace lost electrolytes with oral rehydration solutions if diarrhea is severe.
• Maintain a food diary to identify patterns between meals and symptoms.
• Engage a registered dietitian experienced in gastrointestinal disorders for personalized nutrition plans.

Prevention Tips

Because ZES is typically caused by sporadic gastrinomas, primary prevention is limited. However, several steps can reduce the risk of severe weight loss and complications:

• Early detection – Prompt evaluation of persistent ulcers or unexplained diarrhea can uncover ZES before significant malnutrition occurs.
• Adherence to prescribed acid‑suppression therapy – Skipping doses can lead to breakthrough ulceration and nutrient loss.
• Routine follow‑up imaging – For patients with known gastrinomas, periodic CT, MRI, or PET scans monitor tumor growth.
• Screen for Helicobacter pylori – Eradication reduces ulcer burden, which can mask ZES symptoms.
• Vaccinations – Patients with neuroendocrine tumors may be immunocompromised; stay up‑to‑date with flu, pneumococcal, and COVID‑19 vaccines.
• Nutrition monitoring – Quarterly weight checks and laboratory panels (albumin, pre‑albumin, vitamin levels) help catch early deficits.

Emergency Warning Signs

---

© 2026 HealthInfoMD. All content is for educational purposes and does not replace professional medical advice. For personalized evaluation, consult a qualified healthcare provider.

References:

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed April 2026.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” https://www.niddk.nih.gov. Accessed April 2026.
3. Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome) Treatment.” https://my.clevelandclinic.org. Accessed April 2026.
4. World Health Organization. “Guidelines for the Management of Neuroendocrine Tumors.” WHO Publication, 2023.
5. American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Gastric Acid‑Related Disorders. 2022.

```